Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Publication year range
1.
Am J Med Genet A ; 179(4): 659-662, 2019 04.
Article in English | MEDLINE | ID: mdl-30768759

ABSTRACT

Chromosome 12q15 microdeletion syndrome is characterized by intellectual disability and dysmorphic facial features, but the associations between each of the deleted genes and the phenotypes of 12q15 microdeletion syndrome remain unclear. Recently, the smallest region of overlap in 16 previously reported patients was used to define three candidate genes for the 12q15 microdeletion syndrome: CNOT2, KCNMB4, and PTPRB. Among these three candidate genes, CNOT2 maintains the structural integrity of the carbon catabolite repressor 4 (CCR4)-negative on TATA (NOT) complex, which plays a key role in regulating global gene expression, and is essential for the enzymatic activity of the CCR4-NOT complex. Disruption of the CCR4-NOT complex results in dysregulation of global gene expression, and is associated with various human disease processes, including neuronal diseases. Therefore, CNOT2 haploinsufficiency might account for the neurological features of the 12q15 microdeletion syndrome. Herein, we document a 12-year-old female patient with mild intellectual disability and multiple structural abnormalities including cleft lip and palate and 2-3 toe syndactyly. She exhibited dysmorphic facial features such as upslanting and short palpebral fissures, micrognathia, low-set ears, and hypoplastic antihelix. A microarray analysis showed a de novo 1.32-Mb deletion within 12q15 that included CNOT2 and 14 other genes. Remapping of the 12q15 deletion region in the 16 previously reported patients together with that in the newly identified patient indicated that CNOT2 is the only gene that is commonly deleted. These findings suggest that CNOT2 is the prime candidate for the neurological phenotypes of the 12q15 microdeletion syndrome.


Subject(s)
Abnormalities, Multiple/pathology , Chromosome Deletion , Chromosomes, Human, Pair 12/genetics , Developmental Disabilities/pathology , Intellectual Disability/pathology , Repressor Proteins/genetics , Abnormalities, Multiple/genetics , Child , Developmental Disabilities/genetics , Female , Humans , Intellectual Disability/genetics , Prognosis , Syndrome
2.
Pediatr Emerg Care ; 29(10): 1104-6, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24084609

ABSTRACT

Mumps virus infection primarily affects the salivary glands and may incur various complications. Laryngeal edema is such a rare complication that few adult cases have been reported. We report the first known pediatric patient with mumps with laryngeal edema. An 8-year-old boy developed dyspnea after a rapidly progressive swelling of his face and neck. Laryngoscopy revealed edematous changes in the supraglottic and subglottic regions, and computed tomography confirmed significant laryngeal edema in addition to swelling of the cervical soft tissue and the salivary glands. Laboratory findings revealed a high serum amylase level and confirmed the diagnosis of mumps. Intravenous steroid administration alleviated the dyspnea, although the patient required temporary tracheal intubation to maintain airway patency. He did not need tracheotomy and did not experience any other complications. Laryngeal edema must be regarded as a rare, potentially life-threatening complication of mumps. When mumps is diagnosed with significant swelling of the neck, an emergency airway should be established to prevent airway obstruction.


Subject(s)
Airway Obstruction/etiology , Laryngeal Edema/etiology , Mumps/complications , Airway Obstruction/therapy , Antibiotic Prophylaxis , Child , Combined Modality Therapy , Dexamethasone/therapeutic use , Diagnosis, Differential , Dyspnea/drug therapy , Dyspnea/etiology , Emergencies , Humans , Hypnotics and Sedatives/therapeutic use , Intubation, Intratracheal , Laryngeal Edema/diagnostic imaging , Laryngeal Edema/therapy , Male , Mumps/diagnosis , Neck Pain/etiology , Radiography , Respiration, Artificial
3.
Nihon Shokakibyo Gakkai Zasshi ; 108(4): 605-10, 2011 Apr.
Article in Japanese | MEDLINE | ID: mdl-21467767

ABSTRACT

A 38-year-old man with complaints of nausea, epigastralgia, cough, and decrease body weight was given a diagnosis of advanced gastric cancer (type 4) with carcinomatous lymphangitis of the lung (UM-circ cT3, N3, H0, P0, M1, stage IV, por2). He was treated with combination of docetaxel (DOC) 40 mg/m(2)/day (days 1, 15) and S-1 orally 80 mg/m(2)/day (days 1-7, 15-21), 1 week administered 1 week rest. After 2 courses of treatment, the patient achieved a partial response in the carcinomatous lymphangitis of the lung. Tumor markers decreased and symptoms improved. He experienced grade 2 peripheral neuropathy but with no grade 3 adverse events. Although the prognosis of gastric cancer with carcinomatous lymphangitis is poor. These results indicate that bi-weekly DOC and S-1 combination chemotherapy might be effective for gastric cancer with carcinomatous lymphangitis of the lung.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lung Neoplasms/drug therapy , Lymphangitis/drug therapy , Stomach Neoplasms/drug therapy , Adult , Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Agents/administration & dosage , Docetaxel , Drug Combinations , Humans , Male , Oxonic Acid/administration & dosage , Taxoids/administration & dosage , Tegafur/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL